Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the positions showed up on publicly ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Biotechnology company Moderna Inc. (NASDAQ: MRNA) gained the spotlight in the medical sector as a leader in the race toward a COVID-19 vaccine. Its messenger RNA (mRNA) technology garnered acclaim ...

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but the gains didn't last long. Since reaching a peak last May, Moderna ...

Ratings for Moderna (NASDAQ:MRNA) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ...

Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 28 unusual trades. Delving into the details, we found 17% of traders were bullish, while 64% showed bearish tendencies.

Moderna (MRNA) closed at $34.45 in the latest ... Meanwhile, the Dow gained 0.52%, and the Nasdaq, a tech-heavy index, lost 0.23%. Shares of the biotechnology company have depreciated by 15. ...